Literature DB >> 35399218

An antivenin resistant, IVIg-corticosteroids responsive viper induced thrombocytopenia.

Matteo Turetta1, Fabio Del Ben2, Donatella Londero3, Agostino Steffan1, Pierpaolo Pillinini4.   

Abstract

In this case report the hospital management of an acute, severe thrombocytopenia in a 57-year-old man in the north-east of Italy is reported. Thrombocytopenia developed immediately after the viper bite, despite the absence of clinical signs of envenomation. No hemorrhage, ecchymoses or other signs of coagulopathy developed during the hospitalization; two doses of antivenin FAB-Fragments had no effect on thrombocytopenia, which instead responded promptly to intravenous immunoglobulins (IVIg) and glucocorticoids. Direct and indirect anti-platelet antibodies against anti-GP IIb/IIIa and Ia/IIa were detected during the treatment and turned negative after 20 weeks. The rationale of such off-label treatment is the interpretation of the thrombocytopenia as a venom-induced immune thrombocytopenia which led to splenic sequestration of platelets. To our knowledge, there is no literature about venom-induced immune thrombocytopenia against GP IIb/IIIa and Ia/IIa protein in European countries and subsequent response to IVIg and corticosteroids.
© 2022 The Authors. Published by Elsevier B.V.

Entities:  

Keywords:  Glucocorticoids; Intravenous immunoglobulins; Thrombocytopenia; Viper bite

Year:  2022        PMID: 35399218      PMCID: PMC8990049          DOI: 10.1016/j.toxrep.2022.03.033

Source DB:  PubMed          Journal:  Toxicol Rep        ISSN: 2214-7500


  29 in total

Review 1.  Haemostatically active proteins in snake venoms.

Authors:  Tamara Sajevic; Adrijana Leonardi; Igor Križaj
Journal:  Toxicon       Date:  2011-01-26       Impact factor: 3.033

2.  Differential procoagulant effects of saw-scaled viper (Serpentes: Viperidae: Echis) snake venoms on human plasma and the narrow taxonomic ranges of antivenom efficacies.

Authors:  Aymeric Rogalski; Christoffer Soerensen; Bianca Op den Brouw; Callum Lister; Daniel Dashevsky; Kevin Arbuckle; Alexandra Gloria; Christina N Zdenek; Nicholas R Casewell; José María Gutiérrez; Wolfgang Wüster; Syed A Ali; Paul Masci; Paul Rowley; Nathaniel Frank; Bryan G Fry
Journal:  Toxicol Lett       Date:  2017-08-25       Impact factor: 4.372

3.  Fractionation of Vipera ammodytes venom and seasonal variation of its composition.

Authors:  F Gubensek; D Sket; V Turk; D Lebez
Journal:  Toxicon       Date:  1974-03       Impact factor: 3.033

Review 4.  Snake venoms and coagulopathy.

Authors:  Julian White
Journal:  Toxicon       Date:  2005-04-12       Impact factor: 3.033

5.  Snake venom coagulopathy: use and abuse of blood products in the treatment of pit viper envenomation.

Authors:  J L Burgess; R C Dart
Journal:  Ann Emerg Med       Date:  1991-07       Impact factor: 5.721

Review 6.  Hematologic effects and complications of snake envenoming.

Authors:  Ingrid Berling; Geoffrey K Isbister
Journal:  Transfus Med Rev       Date:  2014-12-18

7.  A nationwide study of Vipera berus bites during one year-epidemiology and morbidity of 231 cases.

Authors:  Christine Karlson-Stiber; Heléne Salmonson; Hans Persson
Journal:  Clin Toxicol (Phila)       Date:  2006       Impact factor: 4.467

8.  Severe Systemic Envenomation Following Vipera berus Bite Managed with ViperaTAb Antivenom.

Authors:  Jessica Hamilton; Juliane Kause; Thomas Lamb
Journal:  Wilderness Environ Med       Date:  2018-10-29       Impact factor: 1.518

9.  Immunological cross-reactivity and neutralisation of European viper venoms with the monospecific Vipera berus antivenom ViperaTAb.

Authors:  Nicholas R Casewell; Ibrahim Al-Abdulla; David Smith; Ruth Coxon; John Landon
Journal:  Toxins (Basel)       Date:  2014-08-19       Impact factor: 4.546

Review 10.  Haemotoxic snake venoms: their functional activity, impact on snakebite victims and pharmaceutical promise.

Authors:  Julien Slagboom; Jeroen Kool; Robert A Harrison; Nicholas R Casewell
Journal:  Br J Haematol       Date:  2017-02-24       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.